Overview

Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see how vincristine, when placed in an oil droplet called a liposome (VSLI), is absorbed, distributed (moved around) and excreted from the the body (pharmacokinetics). This study will also assess the safety of VSLI and to see if VSLI will slow the growth or shrink tumors in patients with metastatic melanoma that has resulted in liver impairment, and who have relapsed after previous therapies.
Phase:
Phase 1
Details
Lead Sponsor:
Acrotech Biopharma LLC
Spectrum Pharmaceuticals, Inc
Treatments:
Vincristine